{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:41:33Z","timestamp":1789875693573,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1-RR024982"],"award-info":[{"award-number":["UL1-RR024982"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001105"],"award-info":[{"award-number":["UL1TR001105"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ijrobp.2021.03.025","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T21:54:03Z","timestamp":1616190843000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2886-0956","authenticated-orcid":false,"given":"Michael R.","family":"Folkert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Zelefsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil B.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Laine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. W. Nathan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Hardee","family":"Neufeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Hornberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa A.","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Roehrborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.03.025_bib0001","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0002","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamaoncol.2015.2316","article-title":"Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer","volume":"1","author":"Kalbasi","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0003","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0004","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","article-title":"American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy","volume":"11","author":"Davis","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","article-title":"American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy","volume":"11","author":"Yamada","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0006","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0007","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ijrobp.2005.05.054","article-title":"Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes","volume":"63","author":"Kupelian","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0008","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0009","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): Final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0010","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0011","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0012","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: Final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0013","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0014","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ijrobp.2020.11.055","article-title":"Influence of geography on prostate cancer treatment","volume":"109","author":"Tang","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0015","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ijrobp.2020.11.064","article-title":"factors influencing noncompletion of radiation therapy among men with localized prostate cancer","volume":"109(5)","author":"Dee","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0016","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"5-year outcomes of a phase I dose escalation study using stereotactic body radiosurgery for patients with low and intermediate risk prostate cancer","volume":"104","author":"Zelefsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0017","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: Survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0018","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0019","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","article-title":"Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-Year outcomes","volume":"1","author":"Fuller","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","article-title":"Stereotactic body radiation therapy for low and intermediate risk prostate cancer\u2014Results from a multi-institutional clinical trial","volume":"59","author":"Hannan","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0021","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.euo.2019.09.006","article-title":"Early tolerance and tumor control outcomes with high-dose ultrahypofractionated radiation therapy for prostate cancer","volume":"3","author":"Zelefsky","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0022","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0023","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ijrobp.2014.03.012","article-title":"Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer","volume":"89","author":"Kim","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0024","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijrobp.2012.12.019","article-title":"A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: Analysis of dosimetric outcomes","volume":"87","author":"Song","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0025","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170672","article-title":"Efficacy of a rectal spacer with prostate SABR-first UK experience","volume":"91","author":"King","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0026","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13014-019-1346-5","article-title":"Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: Toxicity profile and early oncologic outcomes","volume":"14","author":"Hwang","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0027","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","article-title":"Hydrogel spacer prospective multicenter randomized controlled pivotal trial: Dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy","volume":"92","author":"Mariados","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0028","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to rectal separation for prostate radiation therapy: Final results of a phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0029","doi-asserted-by":"crossref","first-page":"E647","DOI":"10.1111\/j.1464-410X.2012.11373.x","article-title":"Application technique: Placement of a prostate-rectum spacer in men undergoing prostate radiation therapy","volume":"110","author":"Hatiboglu","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0030","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0031","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0032","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.025_bib0033","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2020.01.029","article-title":"Target motion mitigation promotes high-precision treatment planning and delivery of extreme hypofractionated prostate cancer radiotherapy: Results from a phase II study","volume":"146","author":"Greco","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621002856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621002856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:52:50Z","timestamp":1759744370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301621002856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0360301621002856"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.025","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}